MY134344A - Substituted imidazolidines, process for their preparation, their use as medicament or diagnostic, and medicament comprising them - Google Patents

Substituted imidazolidines, process for their preparation, their use as medicament or diagnostic, and medicament comprising them

Info

Publication number
MY134344A
MY134344A MYPI20024821A MYPI20024821A MY134344A MY 134344 A MY134344 A MY 134344A MY PI20024821 A MYPI20024821 A MY PI20024821A MY PI20024821 A MYPI20024821 A MY PI20024821A MY 134344 A MY134344 A MY 134344A
Authority
MY
Malaysia
Prior art keywords
medicament
diagnostic
preparation
substituted imidazolidines
imidazolidines
Prior art date
Application number
MYPI20024821A
Inventor
Uwe Dr Heinelt
Hans-Jochen Dr Lang
Armin Dr Hofmeister
Klaus Dr Wirth
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MY134344A publication Critical patent/MY134344A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Abstract

THE INVENTION RELATES TO NOVEL COMPOUNDS OF THE TYPE OF THE IMIDAZOLIDINES OF THE FORMULA 1IN WHICH R1 TO R7 AFRE AS DEFINED IN THE CLAIMS.THEY ARE SUED FOR PREPARING A MEDICAMENT FOR THE TREATMENT OR PROPHYLAXIS OF THE CENTRAL NERVOUS SYSTEM, OF LIPID METABOLISM, OF INFECTION BY ECTOPARASITES, OF DISORDERS OF GALL FUNCTION AND FOR IMPROVING THE RESPIRATORY DRIVE AND ARE THEREFORE USED FOR TREATING RESPIRATORY DISTRESS.ADDITIONALLY, THE COMPOUNDS INCREASE THE MUSCLE TONE OF THE UPPER RESPIRATORY TRACT, THUS SUPPRESSING SNORING.
MYPI20024821A 2001-12-21 2002-12-20 Substituted imidazolidines, process for their preparation, their use as medicament or diagnostic, and medicament comprising them MY134344A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10163239A DE10163239A1 (en) 2001-12-21 2001-12-21 Substituted imidazolidines, process for their preparation, their use as medicaments or diagnostic agents, and medicaments containing them

Publications (1)

Publication Number Publication Date
MY134344A true MY134344A (en) 2007-12-31

Family

ID=7710363

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20024821A MY134344A (en) 2001-12-21 2002-12-20 Substituted imidazolidines, process for their preparation, their use as medicament or diagnostic, and medicament comprising them

Country Status (27)

Country Link
EP (1) EP1461034B1 (en)
JP (1) JP4571803B2 (en)
KR (1) KR100959031B1 (en)
CN (1) CN100339079C (en)
AR (1) AR037932A1 (en)
AT (1) ATE345797T1 (en)
AU (1) AU2002361990B2 (en)
BR (1) BR0215154A (en)
CA (1) CA2470856A1 (en)
CO (1) CO5590925A2 (en)
DE (2) DE10163239A1 (en)
DK (1) DK1461034T3 (en)
ES (1) ES2275945T3 (en)
HR (1) HRP20040573A2 (en)
HU (1) HUP0600836A2 (en)
IL (2) IL162562A0 (en)
MA (1) MA27149A1 (en)
MX (1) MXPA04005388A (en)
MY (1) MY134344A (en)
NO (1) NO20043009L (en)
PE (1) PE20030741A1 (en)
PL (1) PL368940A1 (en)
RS (1) RS53204A (en)
RU (1) RU2004122415A (en)
TW (1) TW200305408A (en)
WO (1) WO2003053434A1 (en)
ZA (1) ZA200404149B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10323701A1 (en) 2003-05-22 2004-12-23 Aventis Pharma Deutschland Gmbh Process for the synthesis of heterocyclic compounds
ES2545903T3 (en) 2003-06-30 2015-09-16 Sumitomo Chemical Company, Limited Asymmetric urea compounds and process for producing asymmetric compounds by reaction of asymmetric addition of conjugate using said compounds as catalyst
DE10341240A1 (en) * 2003-09-08 2005-04-07 Aventis Pharma Deutschland Gmbh Substituted thienoimidazoles, process for their preparation, their use as medicament or diagnostic agent, and medicament containing them
RS58378B1 (en) 2014-07-25 2019-04-30 Taisho Pharmaceutical Co Ltd Phenyl tetrahydroisoquinoline compound substituted with heteroaryl

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236857A (en) * 1961-10-09 1966-02-22 Boehringer Sohn Ingelheim 2-(phenyl-amino)-1, 3-diazacyclopentene-(2) substitution products
US3190802A (en) * 1961-10-09 1965-06-22 Boehringer Sohn Ingelheim Shaving composition and method of using same
EP0070084A3 (en) * 1981-04-24 1983-02-16 Beecham Group Plc Imidazoline derivatives
DE3712385A1 (en) * 1987-04-11 1988-10-27 Boehringer Ingelheim Kg 2-(Phenylimino)imidazolidines
GB9313330D0 (en) * 1993-06-28 1993-08-11 Fujisawa Pharmaceutical Co New compound and its preparation
EP0639573A1 (en) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzocondensed five membered heterocycles, process of their preparation, their use as drug, as diagnostic means and pharmaceuticals containing it
DE4328869A1 (en) * 1993-08-27 1995-03-02 Hoechst Ag Ortho-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic agent, and medicament containing them
KR100257129B1 (en) * 1993-09-11 2000-05-15 성재갑 Novel cephalosphorine antibiotics
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
DE19548812A1 (en) * 1995-12-27 1997-07-03 Hoechst Ag Use of inhibitors of the cellular Na · + · / H · + · exchanger (NHE) for the manufacture of a medicament for respiratory stimulation
DE19633966A1 (en) * 1996-08-22 1998-02-26 Hoechst Ag Phenyl-substituted alkenylcarboxylic acid guanidines, process for their preparation, their use as a medicament or diagnostic agent, and medicament containing them
PT966465E (en) * 1997-03-14 2003-11-28 Vertex Pharma IMFDH ENZYME INHIBITORS
DE19945302A1 (en) * 1999-09-22 2001-03-29 Merck Patent Gmbh Biphenyl derivatives as NHE-3 inhibitors
DE19950898A1 (en) * 1999-10-22 2001-04-26 Aventis Pharma Gmbh New heteroaryl substituted fluoroalkyl-benzoylguanidine derivatives useful for treatment of e.g. ischemias, cardiac infarction, angina, shock, atherosclerosis, cancer and metabolic disorders
DE19960204A1 (en) * 1999-12-14 2001-06-28 Aventis Pharma Gmbh Substituted norlbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostic agents and medicaments containing them
DE10015248A1 (en) * 2000-03-28 2001-10-04 Merck Patent Gmbh Bisamidino compounds as NHE-3 inhibitors
DE10019062A1 (en) * 2000-04-18 2001-10-25 Merck Patent Gmbh Use of known and new 2-guanidino-4-aryl-quinazoline derivatives as NHE-3 inhibitors useful for the treatment of e.g. hypertension, thrombosis, cardiac ischemia, peripheral and CNS ischemia
DE10060292A1 (en) * 2000-12-05 2002-06-20 Aventis Pharma Gmbh Use of substituted benzimidazoles for the manufacture of a medicament for the treatment of diseases which can be influenced by inhibition of the Na + / H + exchanger and medicament containing them

Also Published As

Publication number Publication date
PE20030741A1 (en) 2003-09-29
JP4571803B2 (en) 2010-10-27
WO2003053434A1 (en) 2003-07-03
RU2004122415A (en) 2005-03-27
DE50208809D1 (en) 2007-01-04
CA2470856A1 (en) 2003-07-03
TW200305408A (en) 2003-11-01
KR20040068322A (en) 2004-07-30
HRP20040573A2 (en) 2004-10-31
ATE345797T1 (en) 2006-12-15
ZA200404149B (en) 2006-05-31
CN100339079C (en) 2007-09-26
BR0215154A (en) 2004-10-19
DK1461034T3 (en) 2007-03-26
CN1606440A (en) 2005-04-13
CO5590925A2 (en) 2005-12-30
IL162562A0 (en) 2005-11-20
AR037932A1 (en) 2004-12-22
PL368940A1 (en) 2005-04-04
NO20043009L (en) 2004-07-15
KR100959031B1 (en) 2010-05-20
JP2005516947A (en) 2005-06-09
ES2275945T3 (en) 2007-06-16
MA27149A1 (en) 2005-01-03
EP1461034A1 (en) 2004-09-29
IL162562A (en) 2009-12-24
DE10163239A1 (en) 2003-07-10
AU2002361990A1 (en) 2003-07-09
HUP0600836A2 (en) 2008-04-28
RS53204A (en) 2006-10-27
EP1461034B1 (en) 2006-11-22
MXPA04005388A (en) 2004-10-11
AU2002361990B2 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
YU98003A (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
MXPA03010232A (en) Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders.
TW200504034A (en) Therapeutic agents
MY144483A (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
TW200531689A (en) Therapeutic agents
MXPA04002037A (en) Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity.
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
TNSN04065A1 (en) Treatment of acute myeloid leukemia with indolinone compounds
MXPA05011707A (en) Substituted dihydrochinazolines having antiviral properties.
MY132789A (en) Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals
TW200633986A (en) Therapeutic agents
YU71901A (en) NOVEL MEDICAMENT COMPOSITIONS, BASED ON ANTICHOLINERGICALLY EFFECTIVE COMPOUNDS AND beta-MIMETICS
HK1094425A1 (en) Substituted 2-aminotetralines for the preventive treatment of parkinson's disease
IL176111A0 (en) 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri
MXPA04005156A (en) Adenosine a2a.
SG157231A1 (en) Substituted p-diaminobenzene derivatives
HK1068622A1 (en) Novel heteroaryl derivatives, their preparation and use
YU75603A (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
TW200509933A (en) Therapeutic agents
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
AP1749A (en) Method of treating of demyelinating diseases or conditions.
TW200734324A (en) Therapeutic agents
EP1532131A4 (en) Motilide compounds
PL348108A1 (en) Bile-acid substituted phenyl alkenoyl guanidines, method for the production thereof, use thereof as medicaments or diagnostic agents and medicaments that contain them
SI1606288T1 (en) Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain